Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis

Capkun, Gorana; Lahoz, Raquel; Verdun, E.; Song, Xue; Chen, Weston; Korn, Jonathan R.; Dahlke, Frank; Freitas, Rita; Fraeman, Kathy; Simeone, Jason C; Johnson, Barbara H.; Nordstrom, Beth L.

doi:10.1185/03007995.2015.1014029

Cited by 28 publications

(23 citation statements)

References 26 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have reported that a 4-year history is insufficient to accurately classify MS patients as incident on the basis of claims data [21]. …”

Section: Discussionmentioning

confidence: 99%

Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data

Foulon¹,

Maura²,

Dalichampt³

et al. 2017

J Neurol

View full text Add to dashboard Cite

Data on the prevalence of multiple sclerosis (MS) in France are scarce. National and regional updated estimates are needed to better plan health policies. In this nationwide study, we provided estimates of the prevalence of MS in France in 2012 and mortality rate in 2013. MS cases were identified in the French national health insurance database (SNIIRAM-PMSI) using reimbursement data for disease-modifying treatment, long-term disease status for MS, disability pension for MS, and hospitalisation for MS (MS ICD-10 code: G35). We identified 99,123 MS cases, corresponding to an overall crude prevalence rate of 151.2 per 100,000 inhabitants [95% confidence interval (CI) 150.3–152.2]: 210.0 per 100,000 in women (95% CI 208.4–211.5) and 88.7 per 100,000 in men (95% CI 87.6–89.7). The overall prevalence rate was 155.6 per 100,000 inhabitants (95% CI 154.7–156.6) after standardization on the 2013-European population. We observed a prevalence gradient with a higher prevalence (190–200 per 100,000) in North-Eastern France and a lower prevalence in Southern and Western France (126–140). The crude mortality rate in 2013 was 13.7 per 1,000 MS cases (11.4 in women and 20.3 in men). The standardized mortality ratio was 2.56 (95% CI 2.41–2.72). Our results revise upwards the estimation of MS prevalence in France and confirm the excess mortality of MS patients compared to the general population.Electronic supplementary materialThe online version of this article (doi:10.1007/s00415-017-8513-0) contains supplementary material, which is available to authorized users.

show abstract

“…Previous studies have reported that a 4-year history is insufficient to accurately classify MS patients as incident on the basis of claims data [21]. …”

Section: Discussionmentioning

confidence: 99%

Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data

Foulon¹,

Maura²,

Dalichampt³

et al. 2017

J Neurol

View full text Add to dashboard Cite

show abstract

“…The Truven Health MarketScan® Commercial Claims and Encounters and Medicare Supplemental Research databases were used for the analysis. The databases combines data from >130 million inpatients and outpatients, linking paid claims and encounter data to detailed patient information across locations and types of providers and over time.…”

Section: Methodsmentioning

confidence: 99%

Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Electronic health record (EHR) databases are being used increasingly in the study of MS and its management [9]. MS subtype is clinically relevant for treatment and health care utilization decision making.…”

Section: Introductionmentioning

confidence: 99%

Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data

Truong²,

Kamauu

et al. 2019

Value in Health

View full text Add to dashboard Cite

Background: Relapsing-remitting multiple sclerosis (RRMS) has a major impact on affected patients; therefore, improved understanding of RRMS is important, particularly in the context of real-world evidence. Objectives: To develop and validate algorithms for identifying patients with RRMS in both unstructured clinical notes found in electronic health records (EHRs) and structured/coded health care claims data. Methods: US Integrated Delivery Network data (2010 e2014) were queried for study inclusion criteria (possible multiple sclerosis [MS] base cohort): one or more MS diagnosis code, patients aged 18 years or older, 1 year or more baseline history, and no other demyelinating diseases. Sets of algorithms were developed to search narrative text of unstructured clinical notes (EHR clinical notesebased algorithms) and structured/coded data (claims-based algorithms) to identify adult patients with RRMS, excluding patients with evidence of progressive MS. Medical records were reviewed manually for algorithm validation. Positive predictive value was calculated for both EHR clinical notesebased and claims-based algorithms. Results: From a sample of 5308 patients with possible MS, 837 patients with RRMS were identified using only the EHR clinical notesebased algorithms and 2271 patients were identified using only the claims-based algorithms; 779 patients were identified using both algorithms. The positive predictive value was 99.1% (95% confidence interval [CI], 94.2% e100%) for the EHR clinical notesebased algorithms and 94.6% (95% CI, 89.1%e97.8%) to 94.9% (95% CI, 89.8%e97.9%) for the claims-based algorithms. Conclusions: The algorithms evaluated in this study identified a real-world cohort of patients with RRMS without evidence of progressive MS that can be studied in clinical research with confidence.

show abstract

Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis

Abstract: The methods suggested in this study offer a good foundation for performing real-world research in MS using administrative claims databases, potentially allowing evidence from different studies to be compared and combined more systematically than in current research practice.

Cited by 28 publications

References 26 publications

Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data

Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data

Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis

Identifying Patients With Relapsing-Remitting Multiple Sclerosis Using Algorithms Applied to US Integrated Delivery Network Healthcare Data

Contact Info

Product

Resources

About